SG10201502759TA - Raav-guanylate cyclase compositions and methods for treating leber's congenital amaurosis-1 (lca1) - Google Patents

Raav-guanylate cyclase compositions and methods for treating leber's congenital amaurosis-1 (lca1)

Info

Publication number: SG10201502759TA
Authority: SG; Singapore
Prior art keywords: lca1; raav; methods; guanylate cyclase; congenital amaurosis
Prior art date: 2010-04-23

Application number

SG10201502759TA

Inventor

Shannon Elizabeth Boye

William W Hauswirth

Sanford Leon Boye

Original Assignee

Univ Florida

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-04-23

Filing date

2011-04-22

Publication date

2015-06-29

2011-04-22 Application filed by Univ Florida filed Critical Univ Florida

2015-06-29 Publication of SG10201502759TA publication Critical patent/SG10201502759TA/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y406/00—Phosphorus-oxygen lyases (4.6)
- C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
- C12Y406/01002—Guanylate cyclase (4.6.1.2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

SG10201502759TA 2010-04-23 2011-04-22 Raav-guanylate cyclase compositions and methods for treating leber's congenital amaurosis-1 (lca1) SG10201502759TA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US32752110P	2010-04-23	2010-04-23

Publications (1)

Publication Number	Publication Date
SG10201502759TA true SG10201502759TA (en)	2015-06-29

Family

ID=44533055

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
SG10201800541SA SG10201800541SA (en)	2010-04-23	2011-04-22	Raav-guanylate cyclase compositions and methods for treating leber's congenital amaurosis-1 (lca1)
SG10201502759TA SG10201502759TA (en)	2010-04-23	2011-04-22	Raav-guanylate cyclase compositions and methods for treating leber's congenital amaurosis-1 (lca1)
SG2012076600A SG184876A1 (en)	2010-04-23	2011-04-22	Raav-guanylate cyclase compositions and methods for treating leber's congenital amaurosis-1 (lca1)
SG10201913135YA SG10201913135YA (en)	2010-04-23	2011-04-23	Raav-guanylate cyclase compositions and methods for treating leber's congenital amaurosis-1 (lca1)

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SG10201800541SA SG10201800541SA (en)	2010-04-23	2011-04-22	Raav-guanylate cyclase compositions and methods for treating leber's congenital amaurosis-1 (lca1)

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
SG2012076600A SG184876A1 (en)	2010-04-23	2011-04-22	Raav-guanylate cyclase compositions and methods for treating leber's congenital amaurosis-1 (lca1)
SG10201913135YA SG10201913135YA (en)	2010-04-23	2011-04-23	Raav-guanylate cyclase compositions and methods for treating leber's congenital amaurosis-1 (lca1)

Country Status (27)

Country	Link
US (3)	US9816108B2 (en)
EP (3)	EP2561067B1 (en)
JP (4)	JP5897549B2 (en)
KR (3)	KR20200047642A (en)
CN (2)	CN105821079B (en)
AU (1)	AU2011242527B2 (en)
BR (1)	BR112012026730A8 (en)
CA (1)	CA2796399C (en)
CL (1)	CL2012002969A1 (en)
CO (1)	CO6640236A2 (en)
CY (1)	CY1123008T1 (en)
DK (2)	DK3486320T3 (en)
EA (2)	EA035893B1 (en)
ES (2)	ES2911185T3 (en)
HR (1)	HRP20190144T1 (en)
HU (1)	HUE041571T2 (en)
IL (2)	IL222651B (en)
LT (1)	LT2561067T (en)
MX (1)	MX351865B (en)
NZ (1)	NZ602897A (en)
PL (2)	PL2561067T3 (en)
PT (2)	PT3486320T (en)
RS (1)	RS58434B1 (en)
SG (4)	SG10201800541SA (en)
SI (1)	SI2561067T1 (en)
TR (1)	TR201901377T4 (en)
WO (1)	WO2011133933A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20120322861A1 (en)	2007-02-23	2012-12-20	Barry John Byrne	Compositions and Methods for Treating Diseases
WO2013075008A1 (en)	2011-11-16	2013-05-23	University Of Florida Research Foundation Inc.	Aav dual vector systems for gene therapy
EP3818991A3 (en)	2012-06-19	2021-07-14	University of Florida Research Foundation, Inc.	Compositions and methods for treating diseases
FR3008618A1 (en) *	2013-07-19	2015-01-23	Univ Paris Curie	USE OF COMPOUNDS TO RESTORE THE RESPONSE IN THE LIGHT OF CELLS OF THE RETINA
WO2015013313A2 (en)	2013-07-22	2015-01-29	The Children's Hospital Of Philadelphia	Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
CN105980569A (en)	2013-08-05	2016-09-28	莱顿大学医学中心附属莱顿教学医院	Recombinant aav-crumbs homologue composition and methods for treating lca-8 and progressive rp
GB201420139D0 (en)	2014-11-12	2014-12-24	Ucl Business Plc	Factor IX gene therapy
KR102415896B1 (en)	2015-06-23	2022-06-30	더 칠드런스 호스피탈 오브 필라델피아	Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
CN110892062A (en) *	2017-05-05	2020-03-17	佛罗里达大学研究基金会	Compositions and methods for expressing otic teratoproteins
WO2019046341A2 (en)	2017-08-28	2019-03-07	University Of Florida Research Foundation, Incorporated	Methods and compositions for treating cone-rod retinal dystrophy
KR20200088385A (en) *	2017-11-15	2020-07-22	더 리젠츠 오브 더 유니버시티 오브 미시간	Method for treating viral vector and retinal dystrophy comprising RDH12 coding region
JP7287611B2 (en)	2018-02-07	2023-06-06	学校法人日本医科大学	Improved adeno-associated virus vector
US11660353B2 (en)	2018-04-27	2023-05-30	Decibel Therapeutics, Inc.	Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
CN114144518A (en)	2019-02-15	2022-03-04	爱科霍拉有限公司	Dual leucine zipper kinase inhibitors for gene therapy
JP2024016295A (en) *	2020-11-30	2024-02-07	タカラバイオ株式会社	Method for producing non-enveloped viruses using divalent cations
CN112852976B (en) *	2021-03-17	2023-10-31	湖北省农业科学院畜牧兽医研究所	Molecular marker related to later egg laying characteristics in NCS1 gene of laying hen and application thereof
WO2023285987A1 (en) *	2021-07-14	2023-01-19	Meiragtx Uk Ii Limited	Retgc gene therapy

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4237224A (en)	1974-11-04	1980-12-02	Board Of Trustees Of The Leland Stanford Jr. University	Process for producing biologically functional molecular chimeras
US4554101A (en)	1981-01-09	1985-11-19	New York Blood Center, Inc.	Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4883750A (en)	1984-12-13	1989-11-28	Applied Biosystems, Inc.	Detection of specific sequences in nucleic acids
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en)	1986-02-07	1989-01-24	Cetus Corporation	Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4987071A (en)	1986-12-03	1991-01-22	University Patents, Inc.	RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
AU622104B2 (en)	1987-03-11	1992-04-02	Sangtec Molecular Diagnostics Ab	Method of assaying of nucleic acids, a reagent combination and kit therefore
AU622426B2 (en)	1987-12-11	1992-04-09	Abbott Laboratories	Assay using template-dependent nucleic acid probe reorganization
EP0359789B1 (en)	1988-01-21	1993-08-04	Genentech, Inc.	Amplification and detection of nucleic acid sequences
CA1340807C (en)	1988-02-24	1999-11-02	Lawrence T. Malek	Nucleic acid amplification process
CA1340323C (en)	1988-09-20	1999-01-19	Arnold E. Hampel	Rna catalyst for cleaving specific rna sequences
US5549910A (en)	1989-03-31	1996-08-27	The Regents Of The University Of California	Preparation of liposome and lipid complex compositions
WO1991003162A1 (en)	1989-08-31	1991-03-21	City Of Hope	Chimeric dna-rna catalytic sequences
US5252334A (en)	1989-09-08	1993-10-12	Cygnus Therapeutic Systems	Solid matrix system for transdermal drug delivery
AU6505690A (en)	1989-09-26	1991-04-28	Richard R Behringer	Erythroid-specific gene expression system
US5466468A (en)	1990-04-03	1995-11-14	Ciba-Geigy Corporation	Parenterally administrable liposome formulation comprising synthetic lipids
US6365730B1 (en)	1990-06-19	2002-04-02	Gene Shears Pty. Limited	DNA-Armed ribozymes and minizymes
JP3218637B2 (en)	1990-07-26	2001-10-15	大正製薬株式会社	Stable aqueous liposome suspension
JP2958076B2 (en)	1990-08-27	1999-10-06	株式会社ビタミン研究所	Multilamellar liposome for gene transfer and gene-captured multilamellar liposome preparation and method for producing the same
JP3257675B2 (en)	1990-10-12	2002-02-18	マックス−プランク−ゲゼルシャフトツールフェルデルングデルビッセンシャフテンエー．ファウ．	Modified ribozyme
US5145684A (en)	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
US5399363A (en)	1991-01-25	1995-03-21	Eastman Kodak Company	Surface modified anticancer nanoparticles
DE4216134A1 (en)	1991-06-20	1992-12-24	Europ Lab Molekularbiolog	SYNTHETIC CATALYTIC OLIGONUCLEOTIDE STRUCTURES
WO1993014200A1 (en)	1992-01-07	1993-07-22	Tsi Corporation	Transgenic animal models for alzheimer's disease
US5652094A (en)	1992-01-31	1997-07-29	University Of Montreal	Nucleozymes
WO1993023569A1 (en)	1992-05-11	1993-11-25	Ribozyme Pharmaceuticals, Inc.	Method and reagent for inhibiting viral replication
WO1994002595A1 (en)	1992-07-17	1994-02-03	Ribozyme Pharmaceuticals, Inc.	Method and reagent for treatment of animal diseases
US5543158A (en)	1993-07-23	1996-08-06	Massachusetts Institute Of Technology	Biodegradable injectable nanoparticles
US5631359A (en)	1994-10-11	1997-05-20	Ribozyme Pharmaceuticals, Inc.	Hairpin ribozymes
US5639940A (en)	1994-03-03	1997-06-17	Pharmaceutical Proteins Ltd.	Production of fibrinogen in transgenic animals
US5789655A (en)	1994-05-13	1998-08-04	The Regents Of The University Of California	Transgenic animals expressing artificial epitope-tagged proteins
US5741516A (en)	1994-06-20	1998-04-21	Inex Pharmaceuticals Corporation	Sphingosomes for enhanced drug delivery
US5795587A (en)	1995-01-23	1998-08-18	University Of Pittsburgh	Stable lipid-comprising drug delivery complexes and methods for their production
US5697899A (en)	1995-02-07	1997-12-16	Gensia	Feedback controlled drug delivery system
IE80468B1 (en)	1995-04-04	1998-07-29	Elan Corp Plc	Controlled release biodegradable nanoparticles containing insulin
US5738868A (en)	1995-07-18	1998-04-14	Lipogenics Ltd.	Liposome compositions and kits therefor
US5656016A (en)	1996-03-18	1997-08-12	Abbott Laboratories	Sonophoretic drug delivery system
US5797898A (en)	1996-07-02	1998-08-25	Massachusetts Institute Of Technology	Microchip drug delivery devices
US5783208A (en)	1996-07-19	1998-07-21	Theratech, Inc.	Transdermal drug delivery matrix for coadministering estradiol and another steroid
US5779708A (en)	1996-08-15	1998-07-14	Cyberdent, Inc.	Intraosseous drug delivery device and method
US6225291B1 (en)	1997-04-21	2001-05-01	University Of Florida	Rod opsin mRNA-specific ribozyme compositions and methods for the treatment of retinal diseases
JP4060531B2 (en) *	1998-05-28	2008-03-12	アメリカ合衆国	AAV5 vectors and uses thereof
EP1381276A4 (en) *	2001-04-13	2005-02-02	Univ Pennsylvania	Method of treating or retarding the development of blindness
CN1381579A (en) *	2001-04-18	2002-11-27	上海博德基因开发有限公司	Polypeptide-guanylyl cyclase-13.53 and polynucleotide for coding it
US20030003582A1 (en) *	2001-05-08	2003-01-02	Tranzyme, Inc.	Trans-viral vector mediated gene transfer to the retina
WO2004065576A2 (en) *	2003-01-15	2004-08-05	Millennium Pharmaceuticals, Inc.	Methods and compositions for the treatment of urological disorder using differential expressed polypeptides
EP1616965A1 (en) *	2004-07-16	2006-01-18	AXXAM S.r.l.	Methods and assays for detecting guanylate cyclase activity
WO2006036465A2 (en)	2004-09-03	2006-04-06	University Of Florida	Compositions and methods for treating cystic fibrosis
US7943374B2 (en) *	2005-08-21	2011-05-17	Markus Hildinger	Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
EP2021499A4 (en)	2005-12-16	2010-02-17	Univ Leland Stanford Junior	Functional arrays for high throughput characterization of gene expression regulatory elements
WO2007127428A2 (en)	2006-04-28	2007-11-08	University Of Florida Research Foundation, Inc.	Double-stranded/self-complementary vectors with a truncated cba promoter and methods of gene delivery
AU2008308784B2 (en) *	2007-10-01	2013-07-18	Arrowhead Research Corporation	Self complementary AAV-mediated delivery of interfering RNA molecules to treat or prevent ocular disorders
US8312249B1 (en)	2008-10-10	2012-11-13	Apple Inc.	Dynamic trampoline and structured code generation in a signed code environment
FR2957821B1 (en)	2010-03-24	2014-08-29	Inst Francais Du Petrole	NEW AREA OF CATALYST REGENERATION DIVIDED IN SECTORS FOR REGENERATIVE CATALYTIC UNITS

2011
- 2011-04-22 LT LTEP11726973.8T patent/LT2561067T/en unknown
- 2011-04-22 EA EA201291103A patent/EA035893B1/en unknown
- 2011-04-22 HU HUE11726973A patent/HUE041571T2/en unknown
- 2011-04-22 CA CA2796399A patent/CA2796399C/en active Active
- 2011-04-22 SG SG10201800541SA patent/SG10201800541SA/en unknown
- 2011-04-22 ES ES18198722T patent/ES2911185T3/en active Active
- 2011-04-22 DK DK18198722.3T patent/DK3486320T3/en active
- 2011-04-22 KR KR1020207009258A patent/KR20200047642A/en not_active Application Discontinuation
- 2011-04-22 RS RS20190156A patent/RS58434B1/en unknown
- 2011-04-22 EP EP11726973.8A patent/EP2561067B1/en active Active
- 2011-04-22 NZ NZ602897A patent/NZ602897A/en unknown
- 2011-04-22 AU AU2011242527A patent/AU2011242527B2/en not_active Ceased
- 2011-04-22 MX MX2012012367A patent/MX351865B/en active IP Right Grant
- 2011-04-22 CN CN201610184430.2A patent/CN105821079B/en active Active
- 2011-04-22 TR TR2019/01377T patent/TR201901377T4/en unknown
- 2011-04-22 PL PL11726973T patent/PL2561067T3/en unknown
- 2011-04-22 EA EA202091105A patent/EA202091105A1/en unknown
- 2011-04-22 JP JP2013506347A patent/JP5897549B2/en active Active
- 2011-04-22 KR KR1020197014973A patent/KR20190060881A/en not_active Application Discontinuation
- 2011-04-22 EP EP22151868.1A patent/EP4056700A1/en active Pending
- 2011-04-22 DK DK11726973.8T patent/DK2561067T3/en active
- 2011-04-22 EP EP18198722.3A patent/EP3486320B1/en active Active
- 2011-04-22 PT PT181987223T patent/PT3486320T/en unknown
- 2011-04-22 PL PL18198722T patent/PL3486320T3/en unknown
- 2011-04-22 SI SI201131660T patent/SI2561067T1/en unknown
- 2011-04-22 SG SG10201502759TA patent/SG10201502759TA/en unknown
- 2011-04-22 PT PT11726973T patent/PT2561067T/en unknown
- 2011-04-22 WO PCT/US2011/033669 patent/WO2011133933A2/en active Application Filing
- 2011-04-22 KR KR1020127030665A patent/KR101984145B1/en active IP Right Grant
- 2011-04-22 CN CN201180020530.7A patent/CN102918152B/en active Active
- 2011-04-22 SG SG2012076600A patent/SG184876A1/en unknown
- 2011-04-22 ES ES11726973T patent/ES2711256T3/en active Active
- 2011-04-22 US US13/643,074 patent/US9816108B2/en active Active
- 2011-04-22 BR BR112012026730A patent/BR112012026730A8/en not_active Application Discontinuation
- 2011-04-23 SG SG10201913135YA patent/SG10201913135YA/en unknown
2012
- 2012-10-23 IL IL222651A patent/IL222651B/en active IP Right Grant
- 2012-10-23 CL CL2012002969A patent/CL2012002969A1/en unknown
- 2012-11-21 CO CO12210917A patent/CO6640236A2/en unknown
2015
- 2015-02-16 JP JP2015027502A patent/JP2015091273A/en not_active Withdrawn
2017
- 2017-03-29 JP JP2017065722A patent/JP6533246B2/en active Active
- 2017-10-10 US US15/728,628 patent/US20180100165A1/en not_active Abandoned
2019
- 2019-01-22 HR HRP20190144TT patent/HRP20190144T1/en unknown
- 2019-01-31 CY CY20191100140T patent/CY1123008T1/en unknown
- 2019-02-04 IL IL264649A patent/IL264649B/en active IP Right Grant
- 2019-04-10 JP JP2019075024A patent/JP2019107037A/en not_active Withdrawn
2021
- 2021-12-01 US US17/540,121 patent/US20220186260A1/en active Pending

Also Published As

Publication number	Publication date
EP2561067B1 (en)	2018-11-14
JP2017114914A (en)	2017-06-29
US9816108B2 (en)	2017-11-14
DK3486320T3 (en)	2022-04-11
PL3486320T3 (en)	2022-05-09
WO2011133933A2 (en)	2011-10-27
JP2015091273A (en)	2015-05-14
CY1123008T1 (en)	2021-10-29
MX2012012367A (en)	2012-11-16
AU2011242527B2 (en)	2016-05-19
EA201291103A1 (en)	2013-10-30
IL264649B (en)	2021-01-31
ES2711256T3 (en)	2019-04-30
HUE041571T2 (en)	2019-05-28
JP2013526854A (en)	2013-06-27
SG10201913135YA (en)	2020-02-27
EP4056700A1 (en)	2022-09-14
EP3486320B1 (en)	2022-01-19
EA035893B1 (en)	2020-08-27
JP5897549B2 (en)	2016-03-30
KR20190060881A (en)	2019-06-03
US20180100165A1 (en)	2018-04-12
CN105821079A (en)	2016-08-03
EP3486320A1 (en)	2019-05-22
JP6533246B2 (en)	2019-06-19
HRP20190144T1 (en)	2019-03-22
ES2911185T3 (en)	2022-05-18
JP2019107037A (en)	2019-07-04
TR201901377T4 (en)	2019-02-21
PT3486320T (en)	2022-03-30
LT2561067T (en)	2019-03-12
WO2011133933A3 (en)	2012-01-05
SG184876A1 (en)	2012-11-29
EP2561067A2 (en)	2013-02-27
PT2561067T (en)	2019-02-04
BR112012026730A8 (en)	2018-07-03
KR20130095643A (en)	2013-08-28
CA2796399C (en)	2021-08-24
RS58434B1 (en)	2019-04-30
IL222651A0 (en)	2012-12-31
CN102918152B (en)	2016-04-13
CN102918152A (en)	2013-02-06
CA2796399A1 (en)	2011-10-27
MX351865B (en)	2017-10-30
CO6640236A2 (en)	2013-03-22
EA202091105A1 (en)	2020-12-30
CN105821079B (en)	2021-10-26
BR112012026730A2 (en)	2015-09-22
CL2012002969A1 (en)	2013-05-31
SI2561067T1 (en)	2019-04-30
SG10201800541SA (en)	2018-03-28
KR101984145B1 (en)	2019-05-30
PL2561067T3 (en)	2019-05-31
NZ602897A (en)	2014-09-26
KR20200047642A (en)	2020-05-07
US20130210895A1 (en)	2013-08-15
US20220186260A1 (en)	2022-06-16
IL222651B (en)	2019-02-28
DK2561067T3 (en)	2019-03-11

Publication	Publication Date	Title
IL264649B (en)	2021-01-31	Raav-guanylate cyclase compositions and methods for treating leber's congenital amaurosis-1 (lca1)
HK1250936A1 (en)	2019-01-18	Compositions and methods for treating viral infections
IL239918A0 (en)	2015-08-31	Compositions and methods for treating colitis
HK1185623A1 (en)	2014-02-21	Methods and compositions for treating hemophilia
WO2011056650A9 (en)	2011-09-01	Methods and compositions for treating and preventing viral infections
EP2124985A4 (en)	2011-06-08	Methods and compositions for treating neuropathies
WO2012054862A9 (en)	2012-08-30	Agents, compositions, and methods for treating pruritis and related skin conditions
EP2575825A4 (en)	2014-01-01	Compositions and methods for treating depression
IL210097A0 (en)	2011-02-28	Compositions and methods for treating unfluenza
EP2504428A4 (en)	2013-09-25	Methods and compositions for treating oxalate-related conditions
EP2544655A4 (en)	2014-05-14	Compositions and methods for treating skin
EP2429584A4 (en)	2013-02-20	Methods and compositions for treatment
IL216146A0 (en)	2012-01-31	Methods and compositions for treating lupus
EP2459187A4 (en)	2012-12-26	Compositions and methods for inhibiting hair growth
WO2011137427A9 (en)	2012-04-12	Compositions and methods for treating pulmonary conditions
WO2011057220A9 (en)	2011-08-18	Compositions and methods for treating lymphoma
ZA201305497B (en)	2015-01-28	Methods and compositions for preventing and treating osteoarthritis
EP2536431A4 (en)	2014-01-08	Compositions and methods for inhibiting mmset
HK1167350A1 (en)	2012-11-30	Methods and compositions for protecting and treating neuroinjury
EP2393506A4 (en)	2012-08-01	Methods and compositions for treating neuropathies
IL217764A0 (en)	2012-03-29	Methods and compositions for treating leukemia
EP2424535A4 (en)	2012-10-31	Methods and compositions for treating dry eye
IL219215A0 (en)	2012-06-28	Compositions and methods for treating aspergillosis